Home > Back to Publisher > Report Information

Partnering Terms and Agreements in Diagnostics , 2nd edition

CHI Insight Pharma Reports
November 10, 2010
283 Pages - SKU: CHI6665100

Abstract Table of Contents Related Reports

The Partnering Terms and Agreements in Diagnostics report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies.

Comprehensive directory of diagnostic deals since 2003
Diagnostic contract documents
Diagnostic agreement terms
Diagnostic agreement structure
Top diagnostic deals by value
Most active diagnostic dealmakers

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Executive Summary
Chapter 1 - Introduction
Chapter 2 - Overview of diagnostic dealmaking: 2.1. Introduction; 2.2. The anatomy of diagnostic partnering; 2.3. Litigation and settlement in diagnostics
Chapter 3 - Trends in diagnostic dealmaking: 3.1. Introduction; 3.2. Diagnostic partnering over the years; 3.3. Most active diagnostic dealmakers; 3.4. Bigpharma diagnostic dealmaking activity; 3.5. Bigpharma not active in diagnostics; 3.6. Oncology partnering by deal type; 3.7. Diagnostic M&A activity since 2000
Chapter 4 - Leading diagnostic deals: 4.1. Introduction; 4.2. Top diagnostic deals by value; 4.3. Top diagnostic involving bigpharma; 4.4. Leading diagnostic M&A deals by value
Chapter 5 - Bigpharma diagnostic deals: 5.1. Introduction; 5.2. How to use bigpharma diagnostic partnering deals; 5.3. Bigpharma partnering company profiles; Abbott; Actavis; Alcon Labs; Allergan; Amgen; Apotex; Astellas; AstraZeneca; Baxter International; Bayer; Biogen Idec; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cephalon; Chugai; CSL; Daiichi Sankyo; Dainippon Sumitomo; Eisai; Eli Lilly; Forest Laboratories; Genzyme; Gilead Sciences; GlaxoSmithKline; Hospira; Johnson & Johnson; Kyowa Hakko Kirin; Lundbeck; Meda; Menarini; Merck & Co; Merck KGaA; Mitsubishi Tanabe; Mylan; Novartis; Novo Nordisk; Nycomed Pharma; Otsuka; Pfizer; Ratiopharm; Roche; Sanofi-Aventis; Servier; Shionogi; Shire; Takeda; Teva; UCB; Watson
Chapter 6 - Diagnostic dealmaking directory 2003-2010: 6.1. Introduction; 6.2. Company A-Z; 6.3. By stage of development; Discovery; Pre-clinical; Phase I; Phase II; Phase III; Registration; Marketed; 6.4. By deal type; Asset and product purchase; Collaborative R&D; Co-development; Co-marketing; Co-promotion; Development; Distribution; Joint venture; Licensing; M&A; Manufacturing; Marketing; Promotion; Option; Research; Supply; 6.5. By therapy area; Cardiovascular; Central nervous system; Dermatology; Gastrointestinal; Genitourinary; Hematology; Immunology; Infection; Inflammation; Metabolic; Musculoskeletal; Oncology; Ophthalmics; Respiratory; Animal health
Chapter 7 - Diagnostic partnering resource center: 7.1. Online diagnostic partnering; 7.2. Diagnostic partnering events; 7.3. Further reading on diagnostic dealmaking
Appendices
Appendix 1 - Deal type definitions
Appendix 2 - Example diagnostic partnering agreement
About CurrentPartnering
Figures in report: Figure 1: Components of the typical diagnostic deal structure; Figure 2: Settlement licensing agreements since 2003; Figure 3: Diagnostic partnering since 2000; Figure 4: Most active diagnostic dealmakers 2003-2010; Figure 5: Bigpharma - top 50 - diagnostic deals 2003 to 2010; Figure 6: Inactive bigpharma in diagnostic dealmaking 2003-2010; Figure 7: Diagnostic partnering by deal type since 2003; Figure 8: Diagnostic option deals since 2003; Figure 9: Diagnostic partnering by disease type from 2003; Figure 10: Diagnostic M&A since 2000; Figure 11: Top diagnostic deals by value since 2000; Figure 12: Top diagnostic deals signed by bigpharma value since 2000; Figure 13: Top diagnostic M&A deals by value since 2000; Figure 14: Online partnering resources; Figure 15: Forthcoming partnering events; Figure 16: Deal type definitions; Figure 17: Diagnostics partnering agreement between Inhibitex and 3M, February 2007

Partnering Terms and Agreements in Diagnostics , 2nd edition

Share this report

Other tasks

Research Assistance

Related Markets

General In Vitro Diagnostics Reports

Free Alert Me service